Acute Myeloid Leukemia Clinical Trial

Phase I Dose Escalation Study of Intravenously Administered S64315 in Combination With Orally Administered Venetoclax in Patients With Acute Myeloid Leukaemia.

Summary

The purpose of this study is to determine the safety profile, tolerability and the Recommended Phase 2 Dose of the combination S64315 with venetoclax in patients with Acute Myeloid Leukaemia.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Male or female aged ≥ 18 years;

Patients with cytologically confirmed and documented de novo, secondary or therapy-related AML as defined by World Health Organization (WHO) 2016 classification (Arber, 2016), excluding acute promyelocytic leukaemia (APL, French-American British M3 classification):

With relapsed or refractory disease without established alternative therapy or
Secondary to MDS treated at least by hypomethylating agent and without established alternative therapy or
≥ 65 years not previously treated for AML and who are not candidates for intensive chemotherapy nor candidates for established alternative therapy
Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
Able to comply with study procedures

Adequate renal function within 7 days before the inclusion of the patient defined as:

• Serum creatinine ≤ 1.5 x ULN (upper normal limit) or calculated creatinine clearance (determined by MDRD) > 50 mL/min/1.73m2

Adequate hepatic function within 7 days before the inclusion of the patient defined as:

AST and ALT ≤ 1.5 x ULN
Total serum bilirubin level ≤ 1.5 x ULN, except for patients with known Gilbert's syndrome, who are excluded if total bilirubin > 3.0 x ULN or direct bilirubin > 1.5 x ULN

Exclusion Criteria:

Participant already enrolled and treated in the study
Pregnancy, breastfeeding or possibility of becoming pregnant during the study
Participation in another interventional study requiring investigational treatment intake at the same time or within 2 weeks or at least 5 halflives (whichever is longer) prior to first dose of IMP (participation in non-interventional registries or epidemiological studies is allowed). In case of biologic agents with a long half life such as CART cells, immune checkpoint antibodies, bispecific antibodies a flat wash-out of 28 days will be acceptable
Presence of ≥ CTCAE Grade 2 toxicity (except alopecia of any grade) due to prior cancer therapy, according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCICTCAE, version 4.03).
Known carriers of HIV antibodies
Known history of significant liver disease
Uncontrolled hepatitis B or C infection
Known active acute or chronic pancreatitis
History of myocardial infarction (MI), unstable angina pectoris, coronary artery bypass graft (CABG) within 6 months prior to starting study treatment
Any factors that could increase the risk of QTc prolongation or risk of arrhythmic events.

Study is for people with:

Acute Myeloid Leukemia

Phase:

Phase 1

Estimated Enrollment:

40

Study ID:

NCT03672695

Recruitment Status:

Active, not recruiting

Sponsor:

Institut de Recherches Internationales Servier

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 2 Locations for this study

See Locations Near You

Smilow Cancer Hospital at Yale
New Haven Connecticut, 06511, United States
The University of Texas MD Anderson Cancer Center, Houston, TX
Houston Texas, 77030, United States
Peter MacCallum cancer centrer
Melbourne , , Australia
The Alfred Hospital Department of Haematology
Victoria Park , , Australia
Institut Paoli-Calmettes
Marseille , , France
Hopital Saint-Antoine
Paris , , France
Institut Universitaire du Cancer Toulouse - Oncopole
Toulouse , , France

How clear is this clinincal trial information?

Study is for people with:

Acute Myeloid Leukemia

Phase:

Phase 1

Estimated Enrollment:

40

Study ID:

NCT03672695

Recruitment Status:

Active, not recruiting

Sponsor:


Institut de Recherches Internationales Servier

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.